Related references
Note: Only part of the references are listed.Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade
Michael A. Weber et al.
BLOOD PRESSURE (2016)
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
Paola Fioretto et al.
CARDIOVASCULAR DIABETOLOGY (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
William T. Cefalu et al.
DIABETES CARE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Cardiovascular Disease and Risk Management
[Anonymous]
DIABETES CARE (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
Linong Ji et al.
CLINICAL THERAPEUTICS (2014)
Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Serge A. Jabbour et al.
DIABETES CARE (2014)
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of dapaglflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2014)
Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
Sunder Mudaliar et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Mei Zhang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension
Lawrence A. Leiter et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Rury R. Holman et al.
LANCET (2014)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Steven P. Marso et al.
AMERICAN HEART JOURNAL (2013)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Personalized Management of Hyperglycemia in Type 2 Diabetes Reflections from a Diabetes Care Editors' Expert Forum
Itamar Raz et al.
DIABETES CARE (2013)
Glycemic Variability: Both Sides of the Story
Antonio Ceriello et al.
DIABETES CARE (2013)
Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
Boaz Hirshberg et al.
DIABETES CARE (2013)
Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes
Lizheng Shi et al.
DIABETES CARE (2013)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
Sarah Stark Casagrande et al.
DIABETES CARE (2013)
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Linda G. Mellbin et al.
EUROPEAN HEART JOURNAL (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis
Atsushi Goto et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Variation of Fasting Plasma Glucose: A Predictor of Mortality in Patients with Type 2 Diabetes
Cheng-Chieh Lin et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range
C. J. Bailey et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Postprandial Hyperglycemia and Glycemic Variability Should we care?
Eberhard Standl et al.
DIABETES CARE (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus
James H. O'Keefe et al.
MAYO CLINIC PROCEEDINGS (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Association of hemoglobin A1c with cardiovascular disease and mortality in adults:: The European prospective investigation into cancer in Norfolk
KT Khaw et al.
ANNALS OF INTERNAL MEDICINE (2004)
Share Paper
